typical antipsychotic drugs. Clozapine's preferential binding to limbic rather than to striatal dopamine receptors explains its rela-ABSTRACT: A case is presented of a fatal drug interaction caused tive lack of extrapyramidal side effects. Clozapine is also antagoby ingestion of clozapine (Clozarilி) and fluoxetine (Prozacி).
for the treatment of major depression. Clinical studies have proven Fluoxetine (Prozacி), (‫-)ע‬N-methyl-3-phenyl-3-[(␣,␣,␣-that concomitant administration of fluoxetine and clozapine protrifluoro-p-tolyl)oxy]propylamine hydrochloride, is a selective duces increased plasma concentrations of clozapine and enhances clozapine's pharmacological effects due to suspected inhibition of serotonin reuptake inhibitor, chemically unrelated to tricyclic, tetclozapine metabolism by fluoxetine. Blood, gastric, and urine speciracyclic or other available antidepressant agents, used for the treatmens were analyzed for fluoxetine by gas chromatography/mass ment of major depression (6,7). Fluoxetine is metabolized to an spectrometry (GC/MS) and for clozapine by gas-liquid chromatogactive metabolite, norfluoxetine and other inactive metabolites raphy (GLC). Clozapine concentrations were: plasma, 4.9 g/mL;
(8,9). Pharmacokinetic data for fluoxetine are given in Table 2. gastric contents, 265 mg; and urine, 51.5 g/mL. Fluoxetine concentrations were: blood, 0.7 g/mL; gastric contents, 3.7 mg; and Clozapine therapy has increased due to its effectiveness in treaturine 1.6 g/mL. Norfluoxetine concentrations were: blood, 0.6 ment-resistant schizophrenic cases and a relatively low risk of g/mL, and none detected in the gastric contents or urine. Analysis extrapyramidal side effects (10). It has been combined with fluoxeof the biological specimens for other drugs revealed the presence tine in the effective treatment of psychotic mood disorders (11,12).
of ethanol (blood, 35 mg/dL; vitreous, 56 mg/dL; and urine 153 mg/dL) and caffeine (present in all specimens). The combination
The clinical combination of these medications has resulted in the of these drugs produced lethal concentrations of clozapine and high elevation of plasma clozapine concentrations and increased signs therapeutic to toxic concentrations of fluoxetine. The deceased had of clozapine toxicity (10-15). Elevated clozapine levels with conpulmonary edema, visceral vascular congestion, paralytic ileus, gascomitant administration of fluoxetine have been attributed to fluoxtroenteritis and eosinophilia. These conditions are associated with etine's affinity and selectivity for microsomal oxidases.
clozapine toxicity. The combined central nervous system, respiratory and cardiovascular depression of these drugs was sufficient to Fluoxetine's inhibition of N-dealkylation and N-oxidation of clocause death. The death was determined to be a clozapine overdose zapine via P 450 isozyme 2D6 produces elevated plasma concentradue to a fatal drug interaction.
tions of the parent clozapine (10, 11, 15) . Although the combinations of clozapine/phenytoin and clozapine/fluvoxamine screens of the biological fluids and gastric contents revealed the presence of caffeine and clozapine and metabolites in all specimens. Initial thin layer drug screens on the specimins did not reveal tubes containing potassium oxalate and sodium fluoride. Vitreous fluoxetine or norfluoxetine due masking by the large concentrahumor was collected from the posterior chambers of both eyes and tions of clozapine and its metabolites and the relative small concenstored in sterile Vacutainer tubes. Urine was collected by bladder trations of fluoxetine and norfluoxetine. Clozapine concentrations puncture and stored in a plastic specimen container. Serum and plasma were separated by centrifugation at 2000 rpm for 10 min. Biological fluids were stored at 2 to 4ЊC until analysis. No tissue antidepressants by a combination of thin-layer chromatography, Urine 1.6 g/mL Norfluxetine gas-liquid chromatography, gas chromatography/mass spectrome- and specific colorimetric procedures.
were determined to be 4.9 g/mL in the plasma, 51.5 g/mL in respiratory depression, coma and death. Fatal overdoses have been involved with ingestions of up to 2000 mg of clozapine (5). the urine and 117.8 g/mL (total of 265 mg) in the gastric contents. Fluoxetine concentrations were determined to be 0.7 g/mL in the Clozapine has been combined with numerous other medications (including valproic acid, phenytoin, carbamazepine, fluoxetine, blood, 1.6 g/mL in the urine and 16.5 g/mL (total of 3.7 mg) in the gastric contents. Norfluoxetine concentrations were deterfluvoxamine, paroxetine and sertraline) to treat various neurological disease states (15) . Combination of clozapine with other medimined to be 0.6 g/mL in the blood and none was detected in the gastric contents or urine.
cations which also undergo significant cytochrome P 450 biotransformations has resulted in elevated clozapine serum concentrations and increased incidences of clozapine toxicity (11,15).
Pathological Findings
The combination of clozapine with this type of medication warrants Complete autopsy revealed visceral vascular congestion with careful clinical monitoring of the patient's blood clozapine concenacute passive congestion of the liver and spleen. The deceased had tration and dosage adjustments as needed. Search of the literature pulmonary edema, paralytic ileus of the sigmoid colonic segment, for toxic or fatal drug interactions from concomitant administration esophagitis, gastroenteritis and chronic obstructive pulmonary disof clozapine or fluoxetine and ethanol revealed no reported cases ease with emphysema, fibrosis and mild anthracosis. Foci of scant to date. While the presence of ethanol in the biological fluids of subarachnoid, epicardial and myocardial haemorrhagia were noted.
the deceased indicate that he had consumed and was influenced Minor cutaneous contusions and abrasions were observed. Immuby ethanol prior to his death, it is apparent that he lived a significant nological and histopathological analysis revealed combined toxic number of hours after ingestion of the alcohol and prior to his and viral hepatitis (hepatitis C positive) with hepatic cirrhosis.
death. The combinations of clozapine/phenytoin and clozapine/ Microscopic evaluation of histological sections of the bowel fluvoxamine have produced elevated serum concentrations of clorevealed eosinophilia of the ileocecal valve region.
zapine which were fatal (16) . The pathological findings of pulmonary edema, visceral vascular congestion, paralytic ileus, gastroenteritis and eosinophilia in this case are consistent with Discussion and Conclusions clozapine toxicity as well as the lethal concentration of clozapine found in the deceased. The accounting of the deceased's prescribed The disproportionalities in ethanol concentrations between the blood, vitreous and urine specimens (vitreous/blood ‫ס‬ 1. 16 and medications and the amounts of fluoxetine and clozapine found in the gastric contents of the deceased would indicate that this was urine/blood ‫ס‬ 4.37) indicate that the deceased had consumed a significant amount of ethanol prior to his death [between 27.5 and not an acute massive overdose of either drug but an overdose that was the result of a fatal drug interaction of these two medications. 85.3 g (0.97 and 3.01 oz) of ethanol (two to six 340 g (12 oz) 4% beers) in this 100 kg (220 lb) individual], and that he was in a
The combined central nervous system, respiratory and cardiovascular depression of these drugs was sufficient to cause the death post ethanol absorption phase with approximately 4.1 h to metabolize the ethanol he consumed prior to his death. The low blood of this individual. The death was determined to be a clozapine overdose due to a fatal drug interaction. ethanol concentration at his time of death would have produced minimal dispositional alterations, but not have produced significant Acknowledgments central nervous system impairment of vital physiological functions.
The blood fluoxetine concentration of 0.7 g/mL would be conThe authors wish to thank Freda Rudder and Patricia Miller for sidered a high therapeutic concentration (therapeutic: 0.03 to 0.5 their assistance in preparation of this manuscript. g/mL; toxic: not reported; and lethal: 1.3 to 6.8 g/mL) (9). The blood norfluoxetine concentration of 0.6 g/mL would be References considered a high therapeutic concentration (therapeutic: 0.18 to 0.06 to 1.0 g/mL; toxic: not reported; lethal: 1.6 to 7.1 g/mL) overdose can produce hypotension, seizure, cardiac arrhythmias,
